These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 6314038)

  • 21. Hypercalcemia of malignancy--new insights into an old syndrome.
    Esbrit P
    Clin Lab; 2001; 47(1-2):67-71. PubMed ID: 11214225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypercalcemic factors other than parathyroid hormone-related protein.
    Mundy GR
    Endocrinol Metab Clin North Am; 1989 Sep; 18(3):795-806. PubMed ID: 2673774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of parathyroid hormone-related peptide to the evaluation of hypercalcemia.
    Audran M; Minebois-Villégas A; Lortholary A; Legrand E; Pascaretti C; Giraud P; Subra JF; Boasson M; Jallet P
    Rev Rhum Engl Ed; 1995 Mar; 62(3):189-96. PubMed ID: 7788336
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parathyroid-hormone-related peptide in hematologic malignancies.
    Kremer R; Shustik C; Tabak T; Papavasiliou V; Goltzman D
    Am J Med; 1996 Apr; 100(4):406-11. PubMed ID: 8610726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Humoral mechanisms in neoplastic hypercalcemia].
    Gennari C; Montagnani M; Nami R; Francini G
    Minerva Med; 1984 Feb; 75(6):235-9. PubMed ID: 6324038
    [No Abstract]   [Full Text] [Related]  

  • 27. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer.
    Seyberth HW; Segre GV; Morgan JL; Sweetman BJ; Potts JT; Oates JA
    N Engl J Med; 1975 Dec; 293(25):1278-83. PubMed ID: 1186822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histomorphometric evaluation of the effects of low dose parathyroid hormone administration on cortical bone remodeling in adult dogs.
    High WB; Black HE; Capen CC
    Lab Invest; 1981 May; 44(5):449-54. PubMed ID: 7230731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intact parathyroid hormone assay and total calcium concentration in the diagnosis of disorders of calcium metabolism in dogs.
    Torrance AG; Nachreiner R
    J Vet Intern Med; 1989; 3(2):86-9. PubMed ID: 2715961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
    Haq M; Kremer R; Goltzman D; Rabbani SA
    J Clin Invest; 1993 Jun; 91(6):2416-22. PubMed ID: 8514854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
    Christiansen P
    APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exocrine pancreatic cancer with humoral hypercalcemia.
    Monno S; Nagata A; Homma T; Oguchi H; Kawa S; Kaji R; Furuta S
    Am J Gastroenterol; 1984 Feb; 79(2):128-32. PubMed ID: 6695885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy.
    Insogna KL; Stewart AF; Vignery AM; Weir EC; Namnum PA; Baron RE; Kirkwood JM; Deftos LM; Broadus AE
    Endocrinology; 1984 Mar; 114(3):888-96. PubMed ID: 6546543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostaglandins and hypercalcemic states.
    Seyberth HW; Raisz LG; Oates JA
    Annu Rev Med; 1978; 29():23-9. PubMed ID: 348034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypercalcemia in a case of childhood acute lymphoblastic leukemia.
    Todo S; Imashuku S; Inoda H; Yamanaka H; Hibi S; Tsunamoto K; Esumi N; Fujiwara F; Shimizu Y; Morioka Y
    Jpn J Clin Oncol; 1987 Dec; 17(4):357-62. PubMed ID: 3320403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypercalcemia and abnormal 1,25-dihydroxyvitamin D concentrations in leprosy.
    Ryzen E; Rea TH; Singer FR
    Am J Med; 1988 Feb; 84(2):325-9. PubMed ID: 2841852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypercalcemia and osteoclast proliferation in adult T-cell leukemia.
    Kiyokawa T; Yamaguchi K; Takeya M; Takahashi K; Watanabe T; Matsumoto T; Lee SY; Takatsuki K
    Cancer; 1987 Mar; 59(6):1187-91. PubMed ID: 2880656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma prostaglandin E in patients with cancer with and without hypercalcemia.
    Robertson RP; Baylink DJ; Metz SA; Cummings KB
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1330-5. PubMed ID: 1002818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypercalcemia in chronic myelogenous leukemia: evidence for excessive parathyroid hormone secretion.
    Molho P; Grange MJ; Guéris J; Ballet JJ; Wautier JL; Tobelem G; Caen JP
    Nouv Rev Fr Hematol (1978); 1985; 27(3):189-92. PubMed ID: 3862073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.